Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction

BMC Cardiovascular Disorders

Caroline Kistorp⁵  Allan Flyvbjerg⁴  Jan Frystyk⁴  Jens Faber³  Jens P Goetze³  Morten Schou¹  Heidi M Christensen² 

[1] Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;Departments of Cardiology and Endocrinology, Herlev University Hospital, Ringvej 75, Herlev 2730, Denmark;Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark;The Medical Research Laboratories, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark;Department of Endocrinology, Herlev University Hospital, Herlev, Denmark

关键词: Body mass index;    Chronic heart failure;    Biomarkers;   

Others  :  856833
DOI  :  10.1186/1471-2261-13-80

 received in 2013-04-03, accepted in 2013-09-26,  发布年份 2013

【 摘 要 】

Background

Low body mass index (BMI) is associated with a poor outcome in chronic heart failure (CHF). An inverse association between BMI and adiponectin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been reported. The aim of the present study was to investigate whether novel markers of neurohormonal activation, inflammation, and endothelial dysfunction are associated with BMI in CHF.

Methods

In a cross-sectional study including 171 patients with CHF and a left ventricular ejection fraction (LVEF) ≤45% the impact of BMI on circulating plasma concentrations of adiponectin, α-defensins, high sensitivity C-reactive protein (hsCRP), copeptin, mid-regional pro-adrenomedullin (MR-proADM), NT-proBNP, and mid-regional pro-A-type natriuretic peptide (MR-proANP) were evaluated.

Results

In multivariable linear regression analysis including age, sex, LVEF, New York Heart Association functional classification (NYHA), estimated glomerular filtration rate (eGFR), and diabetes, only NT-proBNP (β = −0.32) and adiponectin (β = −0.39) remained independently associated with BMI. MR-proANP was associated with BMI but adjusting for age attenuated the relation being no longer significant.

Conclusions

Among biomarkers typically increased in patients with CHF only adiponectin and NT-proBNP demonstrated independent inverse associations with BMI. This indicates a direct effect of these two biomarkers enhancing the wasting process seen in CHF.

【 授权许可】

   
2013 Christensen et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al.: Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050-1053.
• [2]Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA: Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008, 156:13-22.
• [3]Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al.: Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012, 122:1022-1036.
• [4]Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al.: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538.
• [5]Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, et al.: Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine 2012, 43:626-634.
• [6]Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al.: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
• [7]McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al.: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007, 28:829-835.
• [8]Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al.: Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 2012, 14:22-31.
• [9]von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al.: Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1973-1980.
• [10]George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al.: Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006, 92:1420-1424.
• [11]Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, et al.: Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011, 54:2515-2524.
• [12]Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P: Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009, 11:567-572.
• [13]von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al.: Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010, 12:484-491.
• [14]Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, et al.: Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring) 2009, 17:1184-1188.
• [15]Morawiec B, Kawecki D: Copeptin: a new marker in cardiology. J Cardiovasc Med (Hagerstown ) 2013, 14:19-25.
• [16]McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al.: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-2196.
• [17]Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS: Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc 2003, 35:1160-1166.
• [18]Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P, et al.: alpha-Defensins and outcome in patients with chronic heart failure. Eur J Heart Fail 2012, 14:387-394.
• [19]Galatius S, Gustafsson F, Nielsen PH, Atar D, Hildebrandt PR: An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J 2002, 144:E2.
• [20]Joseph G, Tarnow L, Astrup AS, Hansen TK, Parving HH, Flyvbjerg A, et al.: Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J Clin Endocrinol Metab 2008, 93:1470-1475.
• [21]Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al.: Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999, 230:177-181.
• [22]Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005, 48:1911-1918.
• [23]Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50:234-236.
• [24]Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005, 51:1823-1829.
• [25]Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119.
• [26]Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J: Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 2008, 19:130-137.
• [27]Masson S, Gori F, Latini R, Milani V, Flyvbjerg A, Frystyk J, et al.: Adiponectin in chronic heart failure: influence of diabetes and genetic variants. Eur J Clin Invest 2011, 41:1330-1338.
• [28]Bhandari SS, Davies JE, Struck J, Ng LL: Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers 2011, 16:281-287.
• [29]Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB: Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice1. Endocrinology 2010, 151:5218-5225.
• [30]Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, et al.: Atrial natriuretic peptide and adiponectin interactions in man 1. PLoS One 2012, 7:e43238.
• [31]Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice 2. Proc Natl Acad Sci U S A 2001, 98:2005-2010.